---
layout: minimal-medicine
title: Tositumomab
---

# Tositumomab
### Generic Name
Tositumomab

### Usage
Tositumomab is a radiolabeled monoclonal antibody used in the treatment of relapsed or refractory CD20-positive, low-grade, follicular, or transformed non-Hodgkin's lymphoma (NHL).  Specifically, it was indicated for patients whose lymphoma progressed during or after treatment with rituximab.  It's important to note that due to the availability of newer and more commonly used anti-CD20 monoclonal antibodies, tositumomab is no longer commercially available in many regions.


### Dosage
Because tositumomab is no longer commercially available, providing specific dosage information is impractical.  Dosage regimens in the past varied depending on the patient's weight, overall health, and the specific clinical context.  The drug was administered intravenously, and the exact dosage and schedule were determined by a physician specializing in oncology.


### Side Effects
Common side effects associated with tositumomab treatment included:

*   Fatigue
*   Nausea
*   Vomiting
*   Fever
*   Chills
*   Rash
*   Infusion-related reactions (such as hypotension or allergic reactions)

Less common, but more serious side effects, could include:

*   Bone marrow suppression (decreased blood cell counts)
*   Infection
*   Cardiotoxicity (heart damage)
*   Severe allergic reactions
*   Second malignancies


If any adverse effects occur, prompt medical attention should be sought.


### How it Works
Tositumomab is a monoclonal antibody that specifically targets the CD20 antigen found on the surface of B-lymphocytes (a type of white blood cell) and B-cell non-Hodgkin lymphomas.  The drug is radiolabeled, meaning it is attached to a radioactive isotope (Iodine-131).  Once injected, tositumomab binds to CD20-positive cells. The radioactive isotope then emits ionizing radiation, directly damaging the cancerous B-cells and causing their death.  Other potential mechanisms of action include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), where the immune system further assists in destroying the targeted cells.


### Precautions
Because tositumomab is no longer available, providing specific precautions is for historical context only.  However, in its past usage, considerable precautions were necessary.  These precautions would likely have included:

*   **Contraindications:** Patients with severe bone marrow suppression or significant hypersensitivity to murine antibodies would have been excluded.
*   **Drug Interactions:**  Potential interactions with other medications that affect bone marrow function or the immune system would have needed careful consideration.
*   **Pregnancy and Breastfeeding:**  Use during pregnancy or breastfeeding would have been strongly discouraged due to the risk of radiation exposure to the fetus or infant.  
*   **Elderly Patients:**  Older adults might have been at increased risk for certain side effects and required careful monitoring.

### FAQs

**Q: Is tositumomab still available?**

A: No, tositumomab is no longer commercially available in many regions due to the advent of newer and more effective treatments for non-Hodgkin's lymphoma.

**Q: What are the alternatives to tositumomab?**

A:  Several other monoclonal antibodies targeting CD20, such as rituximab, ofatumumab, and obinutuzumab, are currently available and are often used as first-line or subsequent treatments for non-Hodgkin's lymphoma.

**Q:  Why was tositumomab discontinued?**

A: While effective for some patients, tositumomab’s use was limited due to its side effect profile and the emergence of newer, more effective, and less toxic anti-CD20 therapies.

**Q: Where can I learn more about treatment options for non-Hodgkin's lymphoma?**

A:  For the most current and comprehensive information on the treatment of non-Hodgkin’s lymphoma, consult with a qualified oncologist or hematologist.  You can also find reliable information from organizations such as the National Cancer Institute (NCI) and the Leukemia & Lymphoma Society (LLS).


**Disclaimer:** This information is for general knowledge and does not constitute medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
